@article{65d9bdbb0e0248659c67b69e33ab3539,
title = "Genomewide association for schizophrenia in the CATIE study: Results of stage 1",
abstract = "Little is known for certain about the genetics of schizophrenia. The advent of genomewide association has been widely anticipated as a promising means to identify reproducible DNA sequence variation associated with this important and debilitating disorder. A total of 738 cases with DSM-IV schizophrenia (all participants in the CATIE study) and 733 group-matched controls were genotyped for 492 900 single-nucleotide polymorphisms (SNPs) using the Affymetrix 500K two-chip genotyping platform plus a custom 164K fill-in chip. Following multiple quality control steps for both subjects and SNPs, logistic regression analyses were used to assess the evidence for association of all SNPs with schizophrenia. We identified a number of promising SNPs for follow-up studies, although no SNP or multimarker combination of SNPs achieved genomewide statistical significance. Although a few signals coincided with genomic regions previously implicated in schizophrenia, chance could not be excluded. These data do not provide evidence for the involvement of any genomic region with schizophrenia detectable with moderate sample size. However, a planned genomewide association study for response phenotypes and inclusion of individual phenotype and genotype data from this study in meta-analyses hold promise for eventual identification of susceptibility and protective variants.",
author = "Sullivan, {P. F.} and D. Lin and Tzeng, {J. Y.} and {Van Den Oord}, E. and D. Perkins and Stroup, {T. S.} and M. Wagner and S. Lee and Wright, {F. A.} and F. Zou and W. Liu and Downing, {A. M.} and J. Lieberman and Close, {S. L.}",
note = "Funding Information: NIMH contract N01 MH90001. We thank Dr Nick Patterson for assistance with the EigenSoft program. We are indebted to the {\textquoteleft}Molecular Genetics of Schizophrenia II{\textquoteright} (MGS-2) collaboration for their exceptional collegiality in making the control samples available to the research community. Control subjects were from the National Institute of Mental Health Schizophrenia Genetics Initiative, and phenotypes and DNA samples were collected by the MGS-2 collaboration whose investigators and co-investigators are Evanston Northwestern Healthcare (North-western University, Evanston, IL, USA; MH059571), Pablo V Gejman, MD (Collaboration Coordinator; PI), Alan R Sanders, MD (Emory University School of Medicine, Atlanta, GA, USA; MH59587), Farooq Amin, MD (PI) (Louisiana State University Health Sciences Center, New Orleans, LA, USA; MH067257), Nancy Buccola APRN, BC, MSN (PI) (University of California-Irvine, Irvine, CA, USA; MH60870), William Byerley, MD (PI) (Washington University, St Louis, MO, USA; U01, MH060879), C Robert Cloninger, MD (PI) (University of Iowa, Iowa, IA, USA; MH59566), Raymond Crowe, MD (PI), Donald Black, MD (University of Colorado, Denver, CO, USA; MH059565), Robert Freedman, MD (PI) (University of Pennsylvania, Philadelphia, PA, USA; MH061675), Douglas Levinson MD (PI) (University of Queensland, QLD, Australia; MH059588), Bryan Mowry, MD (PI) (Mt Sinai School of Medicine, New York, NY, USA; MH59586), Jeremy Silverman, PhD (PI). Financial disclosures Eli Lilly funded the GWAS genotyping done at Perlegen Sciences. Dr Sullivan reports receiving research funding from Eli Lilly in connection with this project. Dr Stroup reports having received research funding from Eli Lilly and consulting fees from Janssen Pharmaceutica, GlaxoSmithKline and Bristol-Myers Squibb. Dr Lieberman reports having received research funding from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutica and Pfizer, and consulting and educational fees from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Pharmaceutica, Novartis, Pfizer and Solvay.",
year = "2008",
month = jun,
doi = "10.1038/mp.2008.25",
language = "English",
volume = "13",
pages = "570--584",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "6",
}